3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leiomyosarcoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostate Cancer Metastatic
1
Mesothelioma, Malignant
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Interventions
Gemcitabine
6
Specimen Handling
4
Cisplatin
4
pembrolizumab
3
enfortumab vedotin
3
atezolizumab
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Carboplatin
3
vinflunine
2
eribulin
2
avelumab
2
Standard of Care
2
Biopsy
2
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
relatlimab
1
pegfilgrastim
1
merphos
1
guadecitabine
1
genexol-PM
1
dehydroftorafur
1
carotuximab
1
Vitamin D
1
Vinblastine
1
Ramucirumab
1
Radiotherapy
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ureteral Neoplasms
×
rucaparib
×
Clear all
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts